Table 1.
Baseline clinical characteristics of the study sample.
| Patient | Diagnosis | Sex | Age at surgery (yrs) | Disease duration (yrs) | UPDRS Part III motor score OFF medication (range 0–132) | Hoehn & Yahr stage | MMSE | Mattis Dementia Rating Scale 2 (Raw, Scaled) | Daily levodopa equivalent dose (LED, mg/day) | Dailytotal cholinesterase inhibitor dose (mg/day) |
|---|---|---|---|---|---|---|---|---|---|---|
| A | PDD | M | 61 | 14 | 56 | 3 | 25 | 124, Scaled 5 (moderately impaired) | 500 | 3 |
| B | PDD | M | 65 | 11 | 50 | 2 | 24 | 116, Scaled 3 (severely impaired) | 923.25 | 4.6 |
| C | PDD | M | 75 | 11 | 39 | 2 | 25 | 126, Scaled 6 (mildly impaired) | 670 | 6 |
| D | PDD | M | 73 | 15 | 62 | 3 | 25 | 110, Scaled 3 (severely impaired) | 380 | 6 |
| E | PDD | M | 46 | 10 | 49 | 2 | 22 | 108, Scaled 2 (severely impaired) | 575 | 12 |
| F | PDD | M | 71 | 15 | 24 | 3 | 21 | 101, Scaled 2 (severely impaired) | 833 | 9 |
| PDD Group Mean (SD) | 65.17 (10.74) | 12.67 (2.25) | 46.67 (13.50) | 2.50 (0.55) | 23.67 (1.75) | 114.17 (9.68) | 646.88 (204.71) | 6.77 (3.24) | ||
| G | DLB | M | 65 | 5 | 35 | 3 | 23 | 126, Scaled 5 (moderately impaired) | 187.5 | 10 |
| H | DLB | M | 73 | 4 | 42 | 2 | 23 | 121, Scaled 4 (moderately impaired) | 375 | 9 |
| I | DLB | F | 73 | 10 | 24 | 3 | 21 | 123, Scaled 5 (moderately impaired) | 1000 | 9.5 |
| J | DLB | M | 75 | 3 | 20 | 2 | 24 | 82, Scaled 2 (severely impaired) | 62.5 | 10 |
| K | DLB | M | 73 | 4 | 16 | 2 | 24 | 125, Scaled 5 (moderately impaired) | 0 | 10 |
| DLB Group Mean (SD) | 71.80 (3.90) | 5.20 (2.77) | 27.40 (10.81) | 2.40 (0.55) | 23.00 (1.22) | 115.40 (18.77) | 325.00 (403.60) | 9.70 (0.45) | ||
Dementia duration was estimated by examining the patient's medical notes and collateral history from the caregiver to determine the time at which cognitive decline began to interfere with normal occupational or social function. The Mattis Dementia Rating Scale 2 Scaled score is corrected for age but not education. SD = standard deviation. UPDRS = Movement Disorders Society Unified Parkinson's Disease Rating Scale. LED calculation as per protocol in Tomlinson et al., 2010.